10-K Filing

BIO-PATH HOLDINGS, INC. CIK: 1133818 FY 2021

Filing Information

Form Type	10-K
Accession Number	`0001558370-22-003298`
Period End Date	20211231
Filing Date	20220310
Fiscal Year	2021
Fiscal Period	FY
XBRL Instance	bpth-20211231x10k_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 59 Income Statement 22 Cash Flow Statement 34 Stockholders Equity 13

Balance Sheet 59 line items

Line Item	Tag	Value	Unit	Period
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash	`Cash`	$23.77M	USD	Point-in-time
Cash	`Cash`	$13.76M	USD	Point-in-time
Preferred Stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred Stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Prepaid drug product	`PrepaidExpenseCurrent`	$1.27M	USD	Point-in-time
Prepaid drug product	`PrepaidExpenseCurrent`	$523.00K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.84M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$928.00K	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$15.96M	USD	Point-in-time
Common Stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$26.14M	USD	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	7.16M	shares	Point-in-time
Common Stock, shares issued	`CommonStockSharesIssued`	4.54M	shares	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$1.10M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	7.16M	shares	Point-in-time
Furniture, fixtures & equipment	`PropertyPlantAndEquipmentGross`	$1.03M	USD	Point-in-time
Common Stock, shares outstanding	`CommonStockSharesOutstanding`	4.54M	shares	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$798.00K	USD	Point-in-time
Less accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$874.00K	USD	Point-in-time
Furniture, fixtures & equipment, net	`PropertyPlantAndEquipmentNet`	$231.00K	USD	Point-in-time
Furniture, fixtures & equipment, net	`PropertyPlantAndEquipmentNet`	$225.00K	USD	Point-in-time
Right of use operating assets	`OperatingLeaseRightOfUseAsset`	$203.00K	USD	Point-in-time
Right of use operating assets	`OperatingLeaseRightOfUseAsset`	$288.00K	USD	Point-in-time
Total Assets	`Assets`	$16.48M	USD	Point-in-time
Total Assets	`Assets`	$26.57M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$106.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$100.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$770.00K	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$975.00K	USD	Point-in-time
Current portion of lease liabilities	`OperatingLeaseLiabilityCurrent`	$94.00K	USD	Point-in-time
Current portion of lease liabilities	`OperatingLeaseLiabilityCurrent`	$82.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$958.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.17M	USD	Point-in-time
Noncurrent lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$236.00K	USD	Point-in-time
Noncurrent lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$153.00K	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.11M	USD	Point-in-time
Total Liabilities	`Liabilities`	$1.41M	USD	Point-in-time
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $.001 par value; 10,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $.001 par value; 200,000 shares authorized; 7,160 and 4,542 shares issued and outstanding, respectively	`CommonStockValue`	$5.00K	USD	Point-in-time
Common stock, $.001 par value; 200,000 shares authorized; 7,160 and 4,542 shares issued and outstanding, respectively	`CommonStockValue`	$7.00K	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$82.29M	USD	Point-in-time
Additional paid in capital	`AdditionalPaidInCapital`	$103.11M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-67.22M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-77.66M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$21.09M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$25.46M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$15.07M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$26.57M	USD	Point-in-time
Total Liabilities & Shareholders' Equity	`LiabilitiesAndStockholdersEquity`	$16.48M	USD	Point-in-time

Income Statement 22 line items

Line Item	Tag	Value	Unit	Period
Research and development	`ResearchAndDevelopmentExpense`	$5.91M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$6.58M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.33M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$4.53M	USD	Annual
Total operating expenses	`OperatingExpenses`	$10.91M	USD	Annual
Total operating expenses	`OperatingExpenses`	$10.44M	USD	Annual
Net operating loss	`OperatingIncomeLoss`	$-10.91M	USD	Annual
Net operating loss	`OperatingIncomeLoss`	$-10.44M	USD	Annual
Interest income	`InvestmentIncomeInterest`	$26.00K	USD	Annual
Interest income	`InvestmentIncomeInterest`	$3.00K	USD	Annual
Total other income	`NonoperatingIncomeExpense`	$3.00K	USD	Annual
Total other income	`NonoperatingIncomeExpense`	$26.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-10.88M	USD	Annual
Net loss	`NetIncomeLoss`	$-10.44M	USD	Annual
Net loss per share, basic (in dollars per share)	`EarningsPerShareBasic`	$-2.83	USD	Annual
Net loss per share, basic (in dollars per share)	`EarningsPerShareBasic`	$-1.55	USD	Annual
Net loss per share, diluted (in dollars per share)	`EarningsPerShareDiluted`	$-2.83	USD	Annual
Net loss per share, diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.55	USD	Annual
Weighted average number of common shares outstanding, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	6.72M	shares	Annual
Weighted average number of common shares outstanding, basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	3.85M	shares	Annual
Weighted average number of common shares outstanding, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	3.85M	shares	Annual
Weighted average number of common shares outstanding, diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	6.72M	shares	Annual

Cash Flow Statement 34 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-10.88M	USD	Annual
Net loss	`NetIncomeLoss`	$-10.44M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$821.00K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$577.00K	USD	Annual
Amortization of right of use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$85.00K	USD	Annual
Amortization of right of use assets	`OperatingLeaseRightOfUseAssetAmortizationExpense`	$79.00K	USD	Annual
Depreciation	`Depreciation`	$76.00K	USD	Annual
Depreciation	`Depreciation`	$72.00K	USD	Annual
Prepaid drug product	`IncreaseDecreaseInPrepaidExpense`	$-750.00K	USD	Annual
Prepaid drug product	`IncreaseDecreaseInPrepaidExpense`	$497.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$915.00K	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$140.00K	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-84.00K	USD	Annual
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-199.00K	USD	Annual
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$85.00K	USD	Annual
Lease liabilities	`IncreaseDecreaseInOperatingLeaseLiabilities`	$95.00K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-9.92M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-10.96M	USD	Annual
Purchases of furniture, fixtures & equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$70.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-70.00K	USD	Annual
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$12.20M	USD	Point-in-time
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$15.85M	USD	Annual
Net proceeds from sale of common stock	`ProceedsFromIssuanceOfCommonStock`	$4.29M	USD	Annual
Net proceeds from exercise of warrants	`ProceedsFromStockOptionsExercised`	$4.16M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$20.01M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$4.29M	USD	Annual
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-6.67M	USD	Annual
Net increase (decrease) in cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$10.02M	USD	Annual
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.76M	USD	Point-in-time
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$20.43M	USD	Point-in-time
Cash, beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$23.77M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$13.76M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$20.43M	USD	Point-in-time
Cash, end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$23.77M	USD	Point-in-time

Stockholders Equity 13 line items

Line Item	Tag	Value	Unit	Period
Beginning Balance	`StockholdersEquity`	$21.09M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$25.46M	USD	Point-in-time
Beginning Balance	`StockholdersEquity`	$15.07M	USD	Point-in-time
Issuance of common stock, net of fees	`StockIssuedDuringPeriodValueNewIssues`	$4.29M	USD	Annual
Issuance of common stock, net of fees	`StockIssuedDuringPeriodValueNewIssues`	$15.85M	USD	Annual
Exercise of warrants, net of fees	`StockIssueDuringPeriodValueWarrantsExercised`	$4.16M	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalOther`	$577.00K	USD	Annual
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalOther`	$821.00K	USD	Annual
Net loss	`NetIncomeLoss`	$-10.88M	USD	Annual
Net loss	`NetIncomeLoss`	$-10.44M	USD	Annual
Ending Balance	`StockholdersEquity`	$21.09M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$25.46M	USD	Point-in-time
Ending Balance	`StockholdersEquity`	$15.07M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.